This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This pilot project will explore the utility of combined pharmacologic manipulation and arterial spin-labeled perfusion MRI (ASL-pMRI) as an in vivo probe of cholinergic function. There is ample data that the cholinergic system plays a key role in cognition, and that cholinergic dysfunction occurs under a variety of conditions, including normal aging, dementia, and delirium. Methods to investigate cholinergic function in vivo are needed to better understand how the cholinergic system is affected in aging and in disease states. Pharmacologic MRI, by measuring the effects of drug challenges on neuronal activity, can provide an indirect measurement of neurotransmitter function with high anatomic resolution. ASL-pMRI is a technique that uses electromagnetic labeling of water in arterial blood as a diffusible tracer, rather than exogenous contrast agents or radioactivity, to generate highly accurate, non-invasive quantitative measurements of cerebral blood flow, and for these reason is ideally suited for pharmacologic MRI. We propose to use ASL-pMRI to more fully characterize the normal cerebral blood flow response to cholinergic modulation, and to correlate these changes in blood flow with cognitive performance. In this study subjects will be tested under 4 different treatment conditions using anticholinergic drugs: 1) scopolamine; 2) mecamylamine; 3) combined scopolamine and mecamylamine; and 4) placebo, in a double blind, placebo-controlled, crossover design. Under each treatment condition subjects will undergo ASL-pMRI scans and detailed cognitive testing. Comparison of global and regional brain perfusion will be made both within- and across-subjects, and correlated with performance on cognitive testing.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR001032-33
Application #
7718942
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
2008-04-01
Project End
2008-05-31
Budget Start
2008-04-01
Budget End
2008-05-31
Support Year
33
Fiscal Year
2008
Total Cost
$985
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
Simpson, Norah S; Scott-Sutherland, Jennifer; Gautam, Shiva et al. (2018) Chronic exposure to insufficient sleep alters processes of pain habituation and sensitization. Pain 159:33-40
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Chung, Chen-Chih; Pimentel Maldonado, Daniela A; Jor'dan, Azizah J et al. (2018) Lower cerebral vasoreactivity as a predictor of gait speed decline in type 2 diabetes mellitus. J Neurol 265:2267-2276
Kline, Emily R; Seidman, Larry J; Cornblatt, Barbara A et al. (2018) Depression and clinical high-risk states: Baseline presentation of depressed vs. non-depressed participants in the NAPLS-2 cohort. Schizophr Res 192:357-363
Dai, Weiying; Duan, Wenna; Alfaro, Freddy J et al. (2017) The resting perfusion pattern associates with functional decline in type 2 diabetes. Neurobiol Aging 60:192-202
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Torres, Vicente E; Abebe, Kaleab Z; Schrier, Robert W et al. (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91:493-500
Irazabal, María V; Abebe, Kaleab Z; Bae, Kyongtae Ty et al. (2017) Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant 32:1857-1865
Seidman, Larry J; Shapiro, Daniel I; Stone, William S et al. (2016) Association of Neurocognition With Transition to Psychosis: Baseline Functioning in the Second Phase of the North American Prodrome Longitudinal Study. JAMA Psychiatry 73:1239-1248
Thermenos, Heidi W; Juelich, Richard J; DiChiara, Samantha R et al. (2016) Hyperactivity of caudate, parahippocampal, and prefrontal regions during working memory in never-medicated persons at clinical high-risk for psychosis. Schizophr Res 173:1-12

Showing the most recent 10 out of 642 publications